ANGO Q3 2025: NanoKnife Now >50% Prostate Cases, CPT Readout Summer
- Mechanical Thrombectomy Growth: The strong performance of AngioVac at a $6.8 million revenue base, combined with its synergistic relationship with AlphaVac for pulmonary embolism treatment, suggests a robust growth platform for the mechanical thrombectomy portfolio.
- NanoKnife Prostate Opportunity: The increasing organic adoption in the prostate treatment segment—with procedures now exceeding other indications—and the forthcoming reimbursement update (first readout in July with a permanent CPT code effective in January) are key catalysts for future revenue growth.
- Targeted Commercial Expansion: The company’s plans to expand its sales force, leveraging existing strengths and training efforts for both mechanical thrombectomy and other platforms like Auryon, signal a focused strategy to accelerate market penetration and revenue growth going forward.
- Reimbursement uncertainty for NanoKnife: Management’s reliance on the upcoming CPT Level 1 Code and reimbursement readout introduces risk. Any delay or unfavorable outcome in these approvals could hinder the expected revenue growth from the prostate indication.
- Risks tied to clinical trial outcomes: The upcoming AMBITION BTK study for the Auryon platform is critical. Any negative or delayed results from this trial could adversely affect market adoption in the below-the-knee indication.
- Execution challenges in sales force expansion: While plans to further expand the mechanical thrombectomy team are in place, there is risk that increased investment in sales could lead to execution complexities or higher operating costs if anticipated growth does not materialize.
-
NanoKnife Reimbursement
Q: What are NanoKnife prostate updates and reimbursement plans?
A: Management noted that prostate treatments now account for over half of NanoKnife procedures, with a clear pathway as the first reimbursement readout is expected this summer, and the CPT code becomes permanent in January. -
AngioVac Base
Q: Is $6.8M AngioVac revenue a sustainable base?
A: Management sees the $6.8 million revenue base as a strong, sustainable foundation, enhanced by the synergy with AlphaVac for PE, positioning AngioVac as a steady growth driver moving forward. -
Thrombectomy Sales
Q: How is the mechanical thrombectomy sales strategy evolving?
A: Management confirmed the current sales team is well-positioned, with plans to expand opportunistically over the year to further capitalize on the growing adoption of the AlphaVac and AngioVac portfolio. -
Auryon EU
Q: What progress is seen with the Auryon EU launch?
A: Management reported strong training and distributor efforts, expecting revenue contributions in Q4 while acknowledging that the EU market remains smaller than the U.S. but is on a sequential growth path. -
AMBITION Study
Q: When will the AMBITION BTK trial start and yield results?
A: Management indicated enrollment is expected to begin in the next quarter, with the study designed to validate benefits in below-the-knee indications, reinforcing Auryon’s comprehensive use case. -
Team Expansion
Q: Will there be significant expansion of the commercial team?
A: Management stated no major investment is planned immediately; however, they will make incremental enhancements as needed, leveraging the existing team’s strong performance.
Research analysts covering ANGIODYNAMICS.